An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors (IGNYTE)
For more information about the trial above please contact the study team:
Principal Investigator, John Kaczmar, at firstname.lastname@example.org, or please call +1 843-792-6691.
Study Coordinator, Kristina Godwin, at email@example.com.
Trial opened at the following institutions: Medical University of South Carolina